Schroder Investment Management Group bought a new position in shares of CytomX Therapeutics, Inc. (NASDAQ:CTMX) during the third quarter, according to its most recent disclosure with the Securities & Exchange Commission. The institutional investor bought 27,089 shares of the biotechnology company’s stock, valued at approximately $489,000. Schroder Investment Management Group owned 0.07% of CytomX Therapeutics as of its most recent SEC filing.

Other institutional investors also recently made changes to their positions in the company. New York State Common Retirement Fund grew its holdings in CytomX Therapeutics by 48.8% during the second quarter. New York State Common Retirement Fund now owns 31,100 shares of the biotechnology company’s stock worth $482,000 after buying an additional 10,199 shares in the last quarter. Goldman Sachs Group Inc. bought a new stake in CytomX Therapeutics during the first quarter worth $190,000. Trexquant Investment LP bought a new stake in CytomX Therapeutics during the third quarter worth $474,000. California State Teachers Retirement System grew its holdings in CytomX Therapeutics by 27.8% during the second quarter. California State Teachers Retirement System now owns 51,430 shares of the biotechnology company’s stock worth $797,000 after buying an additional 11,200 shares in the last quarter. Finally, TIAA CREF Investment Management LLC grew its holdings in CytomX Therapeutics by 183.7% during the second quarter. TIAA CREF Investment Management LLC now owns 169,552 shares of the biotechnology company’s stock worth $2,628,000 after buying an additional 109,791 shares in the last quarter. Institutional investors and hedge funds own 63.18% of the company’s stock.

CytomX Therapeutics, Inc. (NASDAQ:CTMX) opened at $21.57 on Monday. CytomX Therapeutics, Inc. has a 12 month low of $10.40 and a 12 month high of $24.67.

A number of research analysts have issued reports on the company. Cowen restated an “outperform” rating on shares of CytomX Therapeutics in a research note on Thursday, October 5th. BidaskClub upgraded CytomX Therapeutics from a “hold” rating to a “buy” rating in a research note on Friday. ValuEngine downgraded CytomX Therapeutics from a “hold” rating to a “sell” rating in a research note on Friday, December 1st. Zacks Investment Research upgraded CytomX Therapeutics from a “hold” rating to a “buy” rating and set a $24.00 price objective for the company in a research note on Monday, October 16th. Finally, Cantor Fitzgerald assumed coverage on CytomX Therapeutics in a research note on Monday, October 23rd. They issued an “overweight” rating and a $35.00 price objective for the company. Two research analysts have rated the stock with a sell rating, three have given a hold rating and eight have issued a buy rating to the company. The stock presently has a consensus rating of “Hold” and a consensus price target of $31.88.

In other news, insider Sean A. Mccarthy sold 14,340 shares of the stock in a transaction on Friday, December 1st. The stock was sold at an average price of $20.60, for a total transaction of $295,404.00. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, CEO Sean A. Mccarthy sold 19,120 shares of the stock in a transaction on Wednesday, October 4th. The stock was sold at an average price of $24.13, for a total value of $461,365.60. Following the transaction, the chief executive officer now owns 23,365 shares of the company’s stock, valued at approximately $563,797.45. The disclosure for this sale can be found here. Insiders sold a total of 173,009 shares of company stock valued at $3,835,417 in the last 90 days. Corporate insiders own 4.70% of the company’s stock.

TRADEMARK VIOLATION WARNING: This story was originally posted by The Cerbat Gem and is the sole property of of The Cerbat Gem. If you are reading this story on another website, it was illegally copied and reposted in violation of US and international copyright and trademark laws. The original version of this story can be read at https://www.thecerbatgem.com/2017/12/18/schroder-investment-management-group-invests-489000-in-cytomx-therapeutics-inc-ctmx.html.

CytomX Therapeutics Profile

CytomX Therapeutics, Inc is a clinical-stage, oncology-focused biopharmaceutical company. The Company uses its Probody technology platform to create cancer immunotherapies against clinically validated targets, as well as to develop cancer therapeutics against difficult-to-drug targets. Its pipeline is focused on the development of therapies in a set of modalities: Probody cancer immunotherapies, Probody drug conjugates, T-cell engaging Probody bispecifics and ProCAR-NK cell therapies.

Want to see what other hedge funds are holding CTMX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for CytomX Therapeutics, Inc. (NASDAQ:CTMX).

Institutional Ownership by Quarter for CytomX Therapeutics (NASDAQ:CTMX)

Receive News & Stock Ratings for CytomX Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for CytomX Therapeutics and related stocks with our FREE daily email newsletter.